Extra five years of aromatase inhibitors increases disease-free survival in breast cancerBMJ 2016; 353 doi: https://doi.org/10.1136/bmj.i3153 (Published 06 June 2016) Cite this as: BMJ 2016;353:i3153
- Ingrid Torjesen
Extending use of adjuvant aromatase inhibitors from five to 10 years in women treated for primary breast cancer significantly increases rates of disease-free survival and the risk of cancer occurring in the other breast, a study published in the New England Journal of Medicine shows.1 However, extended use of the drugs was not found to affect overall survival.
The study included 1918 postmenopausal women who had had primary breast cancer and had received 4.5 to 6 years of adjuvant therapy with an aromatase inhibitor, preceded in most cases by tamoxifen, and who were now disease free. Within two years of completing treatment with …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial